Yokukansan and its ingredients as possible treatment options for schizophrenia

References

• AndreasenNCUnderstanding the causes of schizophreniaN Engl J Med1999340864564710029652
   PubMed Web of Science ®Google Scholar
• GreenMFWhat are the functional consequences of neurocognitive deficits in schizophrenia?Am J Psychiatry199615333213308610818
   PubMed Web of Science ®Google Scholar
• VenablesPHInput dysfunction in schizophreniaProg Exp Pers Res19647214714348121
   PubMedGoogle Scholar
• ParkSHolzmanPSGoldman-RakicPSSpatial working memory deficits in the relatives of schizophrenic patientsArch Gen Psychiatry199552108218287575101
   PubMed Web of Science ®Google Scholar
• FreedmanRSchizophreniaN Engl J Med2003349181738174914585943
   PubMed Web of Science ®Google Scholar
• SwansonJWHolzerCE3rdGanjuVKJonoRTViolence and psychiatric disorder in the community: evidence from the Epidemiologic Catchment Area surveysHosp Community Psychiatry19904177617702142118
   PubMedGoogle Scholar
• SirisSGSuicide and schizophreniaJ Psychopharmacol200115212713511448086
   PubMed Web of Science ®Google Scholar
• KapurSMamoDHalf a century of antipsychotics and still a central role for dopamine D2 receptorsProg Neuropsychopharmacol Biol Psychiatry20032771081109014642968
   PubMed Web of Science ®Google Scholar
• KaneJHonigfeldGSingerJMeltzerHClozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazineArch Gen Psychiatry19884597897963046553
   PubMed Web of Science ®Google Scholar
• MeltzerHYClinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophreniaPsychopharmacology (Berl)198999 SupplS18S272682729
   PubMed Web of Science ®Google Scholar
• MatsubaraSMeltzerHYEffect of typical and atypical antipsychotic drugs on 5-HT2 receptor density in rat cerebral cortexLife Sci19894515139714062571912
   PubMed Web of Science ®Google Scholar
• UrbanJDVargasGAvon ZastrowMMailmanRBAripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathwaysNeuropsychopharmacology2007321677716554739
   PubMed Web of Science ®Google Scholar
• ConleyRRBuchananRWEvaluation of treatment-resistant schizophreniaSchizophr Bull19972346636749366002
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcEvoyJPClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) InvestigatorsEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353121209122316172203
   PubMed Web of Science ®Google Scholar
• ModestinJDal PianDAgarwallaPClozapine diminishes suicidal behavior: a retrospective evaluation of clinical recordsJ Clin Psychiatry200566453453815816798
   PubMed Web of Science ®Google Scholar
• LindenmayerJPCzoborPVolavkaJChanges in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychoticsAm J Psychiatry2003160229029612562575
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationAmerican Psychiatric AssociationAmerican Association of Clinical EndocrinologistsNorth American Association for the Study of ObesityConsensus development conference on antipsychotic drugs and obesity and diabetesJ Clin Psychiatry200465226727215003083
   PubMed Web of Science ®Google Scholar
• McEvoyJPMeyerJMGoffDCPrevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES IIISchizophr Res2005801193216137860
   PubMed Web of Science ®Google Scholar
• SahaSChantDMcGrathJA systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?Arch Gen Psychiatry200764101123113117909124
   PubMed Web of Science ®Google Scholar
• AizawaRKanbayashiTSaitoYEffects of Yoku-kan-san-ka-chimpi-hange on the sleep of normal healthy adult subjectsPsychiatry Clin Neurosci200256330330412047606
   PubMed Web of Science ®Google Scholar
• IwasakiKKobayashiSChimuraYA randomized, double-blind, placebo-controlled clinical trial of the Chinese herbal medicine “ba wei di huang wan” in the treatment of dementiaJ Am Geriatr Soc20045291518152115341554
   PubMed Web of Science ®Google Scholar
• IwasakiKSatoh-NakagawaTMaruyamaMA randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patientsJ Clin Psychiatry200566224825215705012
   PubMed Web of Science ®Google Scholar
• IwasakiKKatoSMonmaYA pilot study of banxia houpu tang, a traditional Chinese medicine, for reducing pneumonia risk in older adults with dementiaJ Am Geriatr Soc200755122035204017944889
   PubMed Web of Science ®Google Scholar
• HoriguchiJClinical usage of Yi-gan san-schizophrenia, borderline personality disorder, dyskinesia etcSeishin Shinkeigaku Zasshi20121146708718 Japanese23094294
   PubMedGoogle Scholar
• OkamotoHOkamiTIkedaMTakeuchiTEffects of Yoku-kan-san on undifferentiated somatoform disorder with tinnitusEur Psychiatry2005201747515642449
   PubMed Web of Science ®Google Scholar
• de CairesSSteenkampVUse of Yokukansan (TJ-54) in the treatment of neurological disorders: a reviewPhytother Res20102491265127020812276
   PubMed Web of Science ®Google Scholar
• TatenoMUkaiWOnoTSaitoSHashimotoESaitoTNeuroprotective effects of Yi-Gan San against beta amyloid-induced cytotoxicity on rat cortical neuronsProg Neuropsychopharmacol Biol Psychiatry20083271704170718675875
   PubMed Web of Science ®Google Scholar
• MizukamiKAsadaTKinoshitaTA randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementiaInt J Neuropsychopharmacol200912219119919079814
   PubMed Web of Science ®Google Scholar
• KungFCIshiiRLiuHCTakedaMNew possibility of traditional Chinese and Japanese medicine as treatment for behavioral and psychiatric symptoms in dementiaClin Interv Aging2012739339623055705
   PubMed Web of Science ®Google Scholar
• MizukamiKKampo therapy as an alternative to pharmacotherapy using antipsychotic medicines for behavioral and psychological symptoms of dementia (BPSD)Psychogeriatrics200883137141
   Web of Science ®Google Scholar
• MiyaokaTHoriguchiJClinical potential of Yi-gan san (Yokikansan) for psychiatric disordersCurr Psychiatry Rev200954271275
   Google Scholar
• FuruyaMKunishigeKHJThree case of Lewy body disease with hallucination successfully treated with yi-gan sanSeishin Igaku200749417420 Japanese
   Google Scholar
• MiyaokaTFuruyaMYasudaHYi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label studyProg Neuropsychopharmacol Biol Psychiatry200832376176418201810
   PubMed Web of Science ®Google Scholar
• MiyaokaTFuruyaMYasudaHYi-gan san as adjunctive therapy for treatment-resistant schizophrenia: an open-label studyClin Neuropharmacol20093216919471183
   PubMed Web of Science ®Google Scholar
• MiyaokaTNagahamaMTsuchieKCharles Bonnet syndrome: successful treatment of visual hallucinations due to vision loss with Yi-gan sanProg Neuropsychopharmacol Biol Psychiatry200933238238319141308
   PubMed Web of Science ®Google Scholar
• MiyaokaTFuruyaMKristianLYi-gan san for treatment of charles bonnet syndrome (visual hallucination due to vision loss): an open-label studyClin Neuropharmacol2011341242721164340
   PubMed Web of Science ®Google Scholar
• PlummerCKleinitzAVroomenPWattsROf Roman chariots and goats in overcoats: the syndrome of Charles BonnetJ Clin Neurosci200714870971417428664
   PubMed Web of Science ®Google Scholar
• MiyaokaTWakeRFuruyaMYokukansan (TJ-54) for treatment of very-late-onset schizophrenia-like psychosis: an open-label studyPhytomedicine201320765465823453830
   PubMed Web of Science ®Google Scholar
• TakedaAItohHTamanoHYuzuriharaMOkuNSuppressive effect of Yokukansan on excessive release of glutamate and aspartate in the hippocampus of zinc-deficient ratsNutr Neurosci2008111414618510802
   PubMed Web of Science ®Google Scholar
• KawakamiZKannoHUekiTNeuroprotective effects of yokukansan, a traditional Japanese medicine, on glutamate-mediated excitotoxicity in cultured cellsNeuroscience200915941397140719409210
   PubMed Web of Science ®Google Scholar
• KawakamiZIkarashiYKaseYGlycyrrhizin and its metabolite 18 beta-glycyrrhetinic acid in glycyrrhiza, a constituent herb of yokukansan, ameliorate thiamine deficiency-induced dysfunction of glutamate transport in cultured rat cortical astrocytesEur J Pharmacol20106262–315415819818347
   PubMed Web of Science ®Google Scholar
• TabuchiMImamuraSKawakamiZIkarashiYKaseYThe blood–brain barrier permeability of 18β-glycyrrhetinic acid, a major metabolite of glycyrrhizin in Glycyrrhiza root, a constituent of the traditional Japanese medicine yokukansanCell Mol Neurobiol20123271139114622488528
   PubMed Web of Science ®Google Scholar
• MehtaAPrabhakarMKumarPDeshmukhRSharmaPLExcitotoxicity: bridge to various triggers in neurodegenerative disordersEur J Pharmacol20136981–361823123057
   PubMed Web of Science ®Google Scholar
• AghajanianGKMarekGJSerotonin model of schizophrenia: emerging role of glutamate mechanismsBrain Res Brain Res Rev2000312–330231210719157
   PubMedGoogle Scholar
• EgashiraNIwasakiKIshibashiARepeated administration of Yokukansan inhibits DOI-induced head-twitch response and decreases expression of 5-hydroxytryptamine (5-HT)2A receptors in the prefrontal cortexProg Neuropsychopharmacol Biol Psychiatry20083261516152018558456
   PubMed Web of Science ®Google Scholar
• TerawakiKIkarashiYSekiguchiKNakaiYKaseYPartial agonistic effect of yokukansan on human recombinant serotonin 1A receptors expressed in the membranes of Chinese hamster ovary cellsJ Ethnopharmacol2010127230631219913081
   PubMed Web of Science ®Google Scholar
• ImamuraSTabuchiMKushidaHThe blood–brain barrier permeability of geissoschizine methyl ether in Uncaria hook, a galenical constituent of the traditional Japanese medicine yokukansanCell Mol Neurobiol201131578779321442303
   PubMed Web of Science ®Google Scholar
• UedaTUgawaSIshidaYShimadaSGeissoschizine methyl ether has third-generation antipsychotic-like actions at the dopamine and serotonin receptorsEur J Pharmacol20116711–3798621951966
   PubMed Web of Science ®Google Scholar
• GlennonRADukatMGrellaBBinding of beta-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and benzodiazepine receptorsDrug Alcohol Depend200060212113210940539
   PubMed Web of Science ®Google Scholar
• NishiAYamaguchiTSekiguchiKGeissoschizine methyl ether, an alkaloid in Uncaria hook, is a potent serotonin 1A receptor agonist and candidate for amelioration of aggressiveness and sociality by yokukansanNeuroscience201220712413622314317
   PubMed Web of Science ®Google Scholar
• Newman-TancrediAThe importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectivesCurr Opin Investig Drugs2010117802812
   PubMed Web of Science ®Google Scholar
• GaliciRBoggsJDMillerKLBonaventurePAtackJREffects of SB-269970, a 5-HT7 receptor antagonist, in mouse models predictive of antipsychotic-like activityBehav Pharmacol200819215315918332680
   PubMed Web of Science ®Google Scholar
• UchidaNTakasakiKSakataYCholinergic involvement and synaptic dynamin 1 expression in Yokukansan-mediated improvement of spatial memory in a rat model of early Alzheimer’s diseasePhytother Res201327796697222888033
   PubMed Web of Science ®Google Scholar
• IchikawaJDaiJO’LaughlinIAFowlerWLMeltzerHYAtypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatumNeuropsychopharmacology200226332533911850147
   PubMed Web of Science ®Google Scholar
• SernyakMJLeslieDLAlarconRDLosonczyMFRosenheckRAssociation of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophreniaAm J Psychiatry2002159456156611925293
   PubMed Web of Science ®Google Scholar
• IzumiMSekiTIwasakiKSakamotoKChinese herbal medicine Yi-Gan San decreases the lipid accumulation in mouse 3T3-L1 adipocytes by modulating the activities of transcription factors SREBP-1c and FoxO1Tohoku J Exp Med20092191536219713685
   PubMed Web of Science ®Google Scholar